Ilhan Oztop

Dokuz Eylul University, Ismir, İzmir, Turkey

Are you Ilhan Oztop?

Claim your profile

Publications (68)102.98 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Colorectal cancer has a heterogeneous nature that is influenced by the tumour site. Many improvements have been made in identifying and characterizing the genetic alterations between colon and rectal cancers. However, there is not enough information about KRAS mutational differences between rectosigmoid and colon cancers arising elsewhere in the large bowel. The aim of this study was to determine the differences in the frequency of KRAS genetic alterations between rectosigmoid cancers and colon cancers.
    Journal of gastrointestinal oncology 08/2014; 5(4):265-9.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Soft tissue sarcomas (STSs) are rare malignant tumors of embryogenic mesoderm origin. Primary thoracic STSs account for a small percentage of all STSs and limited published information are available on these. This study aimed to identify the prognostic factors for thoracic STS and evaluate the disease's clinical outcomes.Methods The medical records of 109 patients with thoracic STS who were treated between 2003 and 2013 were retrospectively reviewed. Patients’ survival rates were analyzed and potential prognostic factors evaluated.ResultsThe median follow-up period was 29 months (range, 1–121 months). STSs were most frequently localized on the chest wall (n = 42; 38.5%) and lungs (n = 42; 38.5%). The most common histological types were malignant fibrous histiocytoma (n = 23; 21.1%), liposarcoma (n = 17; 15.6%), and leiomyosarcoma (n = 16; 14.7%). The median survival time of all patients was 40.3 months (95% confident interval, 14.22–66.37 months), with 1- and 5-year survival rates being 93.4% and 63.5%, respectively. Univariate analysis of all groups revealed that metastatic stage, unresectability, tumor diameter of >10 cm, tumor location other than the chest wall, and grade-3 diseases were predictable of poor survival. However, only grade-3 diseases and tumor location other than the chest wall were confirmed by multivariate analysis as poor prognostic factors.Conclusions Primary thoracic STSs are rarely seen malignant tumors. Our results indicated that patients with low-grade tumors and those localized on the chest wall often experienced better survival outcomes.
    Thoracic Cancer. 06/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: We aimed to investigate the efficacy and tolerability of a FOLFOX7 regimen in the first-line treatment of metastatic colorectal cancer (mCRC) patients.
    The Turkish journal of gastroenterology: the official journal of Turkish Society of Gastroenterology 04/2014; 25(2):198-204. · 0.48 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The prognostic value of KRAS and BRAF mutation in colorectal cancer (CRC) is very consistent. Several studies have demonstrated an association between these gene mutations and resistance to anti-EGFR based therapies. Wild type KRAS and BRAF is required for a response to CRC therapy. The aim of this study is to identify the frequency of KRAS and BRAF gene mutations in a series of Turkish CRC patients and to evaluate the relationship between the mutations and demographic features in the Turkish population. KRAS and BRAF mutations were analyzed in 220 colorectal tumor tissues. The mutation assays were performed with genomic DNA using automated microarray-based genotyping technology (Autogenomics Inc., Infinity Biofilm Chip Microarray, KRAS-BRAF Assay). Statistical analyses of the data were performed using SPSS (SPSS/Windows version 19.0, SPSS Inc., Chicago, IL, USA). In total, 33.2% of patients possessed a mutant KRAS genotype, and 6.7% of patients harbored BRAF mutations. The most common KRAS mutations were Gly12Asp and Gly12Val. All of the BRAF mutations were V600E. Patients with KRAS mutations did not harbor BRAF mutation. Female patients displayed an increased KRAS mutation frequency compared with male patients (P value =0.027). KRAS and BRAF gene alterations may determine the therapeutic response to anti-EGFR treatments. The utility of these markers was clarified by correlating genotyping studies with demographics and clinical findings. Cancer mutation profiles are influenced by cultural life style, environment and race/ethnicity. Genotype analysis could be used to select patients eligible for treatment. Patients should be classified according to genotypic subgroups for the selection of therapeutic agents.
    Translational Cancer Research 01/2014; 3((2)):160-166.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We performed this study to examine the prevalence of tumor deposits (TD) in gastric adenocarcinomas (GACa), and the relevance of their presence, size and typeto clinical outcome. Ninety six patients, histopathologically diagnosed as GACa following a total/subtotal gastrectomy were included, and clinicopathologic data were recorded. Due to the statistical analysis, the majority of TD(+) cases were of intestinal type and showed vascular invasion. In these cases, the incidence of local recurrence was significantly higher. The majority of GACa of intestinal type with TD were of high grade and showed vascular invasion. Recurrence and death were more commonly encountered among them. The recurrence-free survival (RFS) was significantly shorter in patients with TDs, which was also confirmed by multivariate analysis, and there was a significant difference between both RFS and overall survival of TD(+) and TD(-) cases of intestinal type GACa. In conclusion, in this study, we demonstrate that TDs are not infrequently observed in GACa, they are more commonly associated with the intestinal type and vascular invasive gastric cancers. Our study shows the prognostic impact of TDs, especially regarding the RFS. Therefore, the documentation of TDs might be considered for prospective studies, especially for the intestinal type GACa, a shortcoming of this study.
    Pathology - Research and Practice 01/2014; · 1.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: In this study, we aimed to evaluate the clinicopathological characteristics and prognosis of patients with primary peritoneal carcinoma (PPC), and the effectiveness and toxicity of first-line platinum/taxane combination therapy. Patients and Methods: We retrospectively evaluated 79 patients with PPC, who were treated and followed up between December 2001 and August 2012 at 10 medical oncology clinics. Results: All patients were female, with a median age of 63 years (range 34-79 years). Histopathological diagnoses included primary peritoneal serous carcinoma (PPSC) (n = 69) and mixed epithelial carcinoma of the peritoneum (MEC) (n = 10). Patients received first-line treatment with carboplatin/paclitaxel (n = 67) or cisplatin/paclitaxel (n = 12) combination therapy. Overall response rate, median progression-free survival, and median survival time in the paclitaxel/carboplatin group and the paclitaxel/cisplatin group were 74.6 vs. 75%, 15.6 vs. 37.8 months, and 41 vs. 70.3 months, respectively. In multivariate analysis, favorable prognostic factors were: ECOG performance status 0 (p < 0.001) and optimal cytoreduction (p = 0.03). Conclusion: PPC is a rare, heterogeneous disease. ECOG performance status and optimal cytoreduction are important prognostic factors regarding survival rates. Platinum/taxane combination therapy is an effective and tolerable regimen in this patient group. © 2014 S. Karger GmbH, Freiburg.
    Oncology research and treatment. 01/2014; 37(6):332-8.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: The purpose of this study was to analyze our series of liver resections for metastatic colorectal carcinoma (mCRC) to determine prognostic factors affecting survival and to evaluate the potential roles of neoadjuvant or adjuvant chemotherapy. Materials and Methods: Ninety-nine patients who underwent metastasectomy for liver metastases due to colorectal cancer at the Department of Medical Oncology, 9 Eylul University Hospital between 1996 and 2010 were evaluated in this study. The patients were followed through July 2013. Demographic, perioperative, laboratory, radiological and chemotherapy as well as survival data were obtained by retrospective chart review. Results: In 47 (47.5%) patients, liver metastases were unresectable at initial evaluation; the remaining 52 (52.5%) patients exhibited resectable liver metastases. Simultaneous hepatic resection was applied to 52 (35.4%) patients with synchronous metastasis, whereas 5 (64.5%) patients underwent hepatic resection after neoadjuvant chemotherapy. Forty-two patients with metachronous metastasis underwent hepatic resection following neoadjuvant chemotherapy. R0 resection was obtained in 79 (79.8%) patients. A second hepatectomy was performed in 22 (23.2%) patients. Adjuvant chemotherapy was given to 85 (85.9%) patients after metastasectomy. The median disease-free and overall survivals after initial metastasectomy were 12 and 37 months, respectively, the 1-year, 3-year and 5-year disease-free survival (DFS) and overall survival (OS) rates being 46.5%, 24.3% and 17.9%and 92.3%, 59.0% and 39.0%, respectively. On multivariate analysis, the primary tumor site, tumor differentiation, resection margin and DFS were independent factors predicting better overall survival. Conclusions: In selected cases, hepatic metastasectomy for mCRC to the liver can result in long-term survival. Neoadjuvant chemotherapy did not exert a positive effect on DFS or OS. Adjuvant chemotherapy also did not appear to impact DFS and OS.
    Asian Pacific journal of cancer prevention: APJCP 01/2014; 15(13):5195-200. · 1.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The development of brain metastases (BMs) was associated with poor prognosis in melanoma patients. Patients with BMs have a median survival of <6 months. Melanoma is the third most common tumor to metastasize to the brain with a reported incidence of 10-40 %. Our aim was to identify factors predicting development of BMs and survival. We performed a retrospective analysis of 470 melanoma patients between 2000 and 2012. The logistic regression analyses were used to identify the clinicopathological features of primary melanoma that are predictive of BMs development and survival after a diagnosis of brain metastases. There were 52 patients (11.1 %) who developed melanoma BMs during the study period. The analysis of post-BMs with Kaplan-Meier curves has resulted in a median survival rate of 4.1 months (range 2.9-5.1 months). On logistic regression analysis site of the primary tumor on the head and neck (p = 0.002), primary tumor thickness (Breslow >4 mm) (p = 0.008), ulceration (p = 0.007), and pathologically N2 and N3 diseases (p = 0.001) were found to be significantly associated with the development of BMs. In univariate analysis, tumor thickness and performance status had a significant influence on post-BMs survival. In multivariate analysis, these clinicopathologic factors were not remained as significant predictive factors. Our results revealed the importance of primary tumor characteristics associated with the development of BMs. Ulceration, primary tumor thickness, anatomic site, and pathologic ≥N2 disease were found to be significant predictors of BMs development.
    Journal of Cancer Research and Clinical Oncology 11/2013; · 2.91 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: CD40, a tumor necrosis factor receptor family member, is expressed in a variety of cell types. This widespread expression suggests that CD40 may play an important role in normal physiology and disease pathogenesis. The objective of the current study was to investigate the expression of CD40, and its association with clinicopathological features and survival in patients with pancreatic ductal adenocarcinoma. CD40 expression was assessed in 53 pancreatic ductal adenocarcinoma surgical specimens by immunohistochemistry, and expression was correlated with patient clinicopathological parameters and outcome. Among 53 pancreatic cancer specimens, CD40 expression was detected in 13 specimens (24.5%), and peritumoral lymphocytes were present in 45 specimens (84.9%). Patients with CD40-positive tumors exhibited prolonged median disease-free survival (DFS) compared with patients with CD40-negative tumors (15.60 +/- 3.87 versus 10.03 +/- 1.92); however, this was not significant (p = 0.845). Patients with peritumoral lymphocytic reaction exhibited prolonged median DFS compared with patients without peritumoral lymphocytes (10.96 +/- 1.40 vs. 7.60 +/- 0.47); however, this was not significant (p = 0.624). Patients with peritumoral lymphocytic reaction exhibited higher median overall survival compared with patients without peritumoral lymphocytes (15.20 +/- 1.78 vs. 10.13 +/- 1.39); however, again this was not significant (p = 0.100). These results suggest that CD40 expression on pancreatic cancer cells and peritumoral lymphocytic reaction may serve as prognostic markers.
    Hepato-gastroenterology 09/2013; 60(128):2085-93. · 0.77 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: 5-Fluorouracil (5-FU), the mainstay of solid tumor chemotherapy over the past 40 years, induces grade III-IV toxicities in up to 15% of patients with polymorphisms in the dihydropyrimidine dehydrogenase (DPYD), thymidylate synthase (TYMS), and methylenetetrahydrofolate reductase (MTHFR) genes. These toxicities include mucositis, neutropenia, nausea, diarrhea, myelosuppression, hand-foot syndrome, and rare ocular adverse effects. Here, we present the case of a female patient with rectal cancer who received 5-FU-based chemotherapy and developed grade III hand-foot syndrome and rare acute ocular adverse effects. Genetic analysis revealed that the patient had an 85T>C mutation in the DPYD gene resulting in a DPYD*9A allele. The clinical and molecular observations indicate that DPYD deficiency may be responsible for the severe ocular adverse effects observed in 5-FU-treated patients. Application of personalized therapy based on molecular testing should help clinicians provide the most effective chemotherapy agents and dose modifications for each patient, although further population-based pharmacogenetic trials for the 5-FU metabolism-related genes are necessary to minimize adverse effects and enhance clinical outcomes.
    American journal of therapeutics 07/2013; · 1.29 Impact Factor
  • Source
    Dogan Koca, Ilhan Oztop, Ugur Yilmaz
    [Show abstract] [Hide abstract]
    ABSTRACT: This study is aimed to evaluate patients with non-metastatic rectal cancer who could not be operated due to any reason and were treated with chemoradiotherapy alone or chemotherapy following chemoradiotherapy. Patients with locally advanced non-metastatic rectal cancer, who were treated and followed-up were evaluated. Totally 263 patients with stage II and III rectal cancer were evaluated. It was determined that 14 (5.2%) of the patients with locally advanced stages received chemoradiotherapy alone or chemotherapy following chemoradiotherapy, and they were followed-up instead of undergoing operation. The baseline assessments revealed that 8 (57.1%) patients had clinical stage II, and 6 (42.9%) patients had clinical stage III diseases. Recurrence was detected in 3 (21.4%) patients. 6 (42.9%) patients died, and death due to rectal cancer progression was detected in 2 (14.3%) patients. Median progression-free survival was 25 months (8 to 68 months), median overall survival was 35 months (12 to 68 months), overall survival rates in 1, 3 and 5 years were 92.9%, 69.8% and 52.4%, respectively. Chemoradiotherapy alone or subsequent chemotherapy after chemoradiotherapy may be suitable for patients with non-metastatic locally advanced rectal cancer who could not be operated due to any reason.
    Journal of gastrointestinal oncology 06/2013; 4(2):193-7.
  • European journal of cancer (Oxford, England: 1990) 04/2013; · 4.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: The purpose of our study was to evaluate the perioperative complications, toxicity, mortality rates after cytoreductive surgery (CRS), and effects of hyperthermic intraperitoneal chemotherapy (HIPEC) used in the treatment of peritoneal surface malignancies. METHODS: Between September 2007 and March 2012, we performed 118 CRS and HIPEC with the closed abdominal technique on 115 patients with peritoneal carcinomatosis (PC). Systemic toxicities were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 criteria and were analyzed from a prospectively collected database. RESULTS: The mean age of patients was 53.4 (range, 20-82) years; 76.3 % were female. PC was synchronous to primary cancer in 53.4 % of patients, metachronous in 41.5 %, and recurrent in 5.1 % of the patients. PCI was ≥15 in 53.4 % of the patients, and CC-0 cytoreduction was achieved in 68.5 % of the patients. Perioperative mortality was observed in 9 (7.6 %) patients. A total of 98 complications were observed in 46 (39.0 %) patients, and 4 patients underwent 6 reoperations for perioperative surgical complications. We observed toxicity in 25.4 % of the patients, nephrotoxicity in 18.6 %, and hematological toxicity in 13.6 % of patients. No significant difference was observed among age, gender, PCI and CC scores, origin of the primary tumor, and occurrence of toxicity and surgical complications. Prolonged operation times resulted in higher complication and/or toxicity rates (P < 0.01). CONCLUSIONS: Cytoreductive surgery and HIPEC is a combined treatment strategy for peritoneal surface malignancies with acceptable complication and toxicity rates.
    Annals of Surgical Oncology 03/2013; · 4.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. KIT gene mutations have great importance for GISTs. This study evaluated the relationship between KIT mutations and GIST clinicopathologic features to define region-specific and population-specific differences. Genomic DNA was extracted from 60 GISTs, and polymerase chain reaction was performed for KIT gene exons 9, 11, 13, and 17. Polymerase chain reaction amplicons were sequenced in both directions. This study represents the first mutation data of the KIT gene in GISTs from a Turkish population and reports novel mutations. The mutation rate in exon 11 (46.7%) was remarkably higher than those of the other exons (8.3% for exon 9; 11.7% for exon 13; 1.7% for exon 17). There was an association between malignancy potential and the presence of KIT mutations (odds ratio=3.18). Cases with mutations in codons W557-K558 in exon 11 had 11-fold greater risk of malignancy when compared with those without a mutation in this exon (odds ratio=11). We report different mutations than those previously reported, which emphasizes the importance of personalized medicine that could be empowered by the use of bioinformatics tools in the diagnostic process and therapeutic approaches.
    Applied immunohistochemistry & molecular morphology: AIMM / official publication of the Society for Applied Immunohistochemistry 02/2013; · 1.63 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: The c-kit proto-oncogene (KIT) exon 9, 11, 13 and 17 activation mutations are associated with clinical behaviour in gastrointestinal stromal tumours whose biological behaviour is highly variable. The purpose of this study is to identify frequency of KIT gene exon 9, 11, 13 and 17 mutations and associate them with histopathologic features for the first time in the Turkish population. Methods: DNA’s were isolated from sixty patients formalin fixed paraffin embedded tumour tissue’s which were diagnosed as gastrointestinal stromal tumour between 2006 and 2010 years, by using spin column method. Isolated DNA’s were sequenced by capillary electrophoresis based DNA sequencing system for presence of mutations in KIT gene exons 9, 11, 13 and 17. Results: KIT mutations frequencies defined for exon 9, 11, 13 and 17 as 8.3%, 47.5%, 11.7% and 1.7% respectively. According to the correlation analysis, the presence of overall mutations and exon 11 mutations of males were higher than those of females (p=0.004 and p=0.003). Small intestine tumours mutation frequency was higher than stomach tumours (p=0.05). Conclusion: In conclusion, this study represents the first mutational results from Turkish gastrointestinal stromal tumour patients. Our cases showed different mutational trend when compared to other reports and this condition exhibits the significance of personalized medicine which could be intensified by the use of genotyping tools in the cancer management. Redefining the molecular features associated with tumour behaviour is important for management of diagnostic and therapy processes in gastrointestinal stromal tumours.
    Türk Biyokimya Dergisi / Turkish Journal of Biochemistry 01/2013; 38((1)):5-12. · 0.21 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: The aim of this study was to evaluate the efficacy and tolerability of a gemcitabine, 5-fluorouracil and leucovorin (GEMFUFOL) chemotherapy regimen as first line treatment of metastatic biliary tract cancer. Materials and Methods: All patients received folinic acid 400 mg/m2 on day 1, 5-fluorouracil bolus 400 mg/ m2 on day 1, IV infusion of 5-fluorouracil 2400 mg/m2 over 46 hours, and gemcitabine 1250 mg/m2 on day 1. Results: A total of 29 patients with metastatic biliary tract cancer received GEMFUFOL regimen as the first- line treatment. The mean follow-up was 22.1 months (95%CI, 12.5-31.8). One patient (3.4%) achieved complete response, 5 (17.2%) had partial response, and 4 (13.8%) had stable disease. The median progression-free survival was 3.3 months (95%CI, 2.9-3.7), and the median overall survival was 8.8 months (95%CI, 3.5-14). The 1-year and 2-year survival rates were 58.6% and 30%, respectively. Grade 3 and 4 toxicity included neutropenia in 4 patients (13.7%), thrombocytopenia in 2 (6.8%), anemia in 2 (6.8%), and alopecia in 1 (3.4%). Two patients (6.8%) developed febrile neutropenia. A dose reduction was achieved in 8 patients (27.6%) while 5 patients had extended-interval dosage (17.2%) for toxicity. Conclusions: The GEMFUFOL chemotherapy regimen was generally efficacious and tolerable as a first-line treatment of metastatic biliary tract cancer.
    Asian Pacific journal of cancer prevention: APJCP 01/2013; 14(9):5263-7. · 1.50 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: To investigate epidermal growth factor receptor (EGFR) gene mutations in patients with non- small cell lung cancer (NSCLC) and to analyze any relationship with clinicopathological features and prognosis. Materials and Methods: EGFR gene exons 18-21 in 48 specimens of paraffin-embedded tumor tissue from NSCLC patients were amplified by PCR, followed by direct sequencing and analysis of links to clinicopathological features and prognosis. Results: EGFR mutations were detected in 18 of 48 (42.6%) patients with NSCLC. There were 9 cases of mutations in exon 20, 7 in exon 19 and 2 in exon 21. Mutations were more frequently observed in women (5/7 pts, 71.4%) than in men (13/41 pts, 31.7%) (p=0.086) and in non-smokers (5/5 pts, 100%) than smokers (13/43 pts, 30.2%). There was negative correlation of EGFR mutations with smoking status (p=0.005). EGFR mutations were more frequently observed with adenocarcinoma histology (13/32 pts, 40.6%) than in other types (5/16 pts, 31.3%) (p=0.527). The patients with EGFR mutations had better survival than those with wild- type EGFR (p=0.08). There was no association of EGFR mutations with metastatic spread. Conclusions: EGFR mutations in NSCLC were here demonstrated more frequently in females, non-smokers and adenocarcinoma histology in the western region of Turkey. Patients with EGFR mutations have a better prognosis.
    Asian Pacific journal of cancer prevention: APJCP 01/2013; 14(6):3705-9. · 1.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: The combination of docetaxel, cisplatin, and 5-fluorouracil (DCF) is an effective but highly toxic regimen for the treatment of advanced gastric cancer. To improve tolerability while maintaining the efficacy of the DCF regimen, we developed a modified DCF regimen including an infusional 5-fluorouracil administration according to the de Gramont regimen. METHODS: In this study, 70 patients with advanced gastric cancer were treated. Each 2-week cycle consisted of docetaxel (60 mg/m(2)), cisplatin (50 mg/m(2)), a 5-fluorouracil (400 mg/m(2)) IV bolus, and 5-fluorouracil (2,400 mg/m(2)) IV over 46 h plus leucovorin (400 mg/m(2)) IV over 2 h. RESULTS: The median progression-free survival and overall survival were 9.0 months (95 % CI, 7.1-10.9) and 10.8 months (95 % CI, 7.4-14.2), respectively; the 1-year and 2-year overall survival rates were 46.3 and 18.4 %, respectively. Twenty-nine (41.4 %) partial responses, 19 (27.1 %) stable disease, and 22 (31.4 %) progression of disease were observed. Grade 3-4 toxicities included neutropenia (37.1 %), febrile neutropenia (15.7 %), thrombocytopenia (10.0 %), anemia (8.6 %), nausea and vomiting (10.0 %), stomatitis (5.7 %), infection (8.6 %), and diarrhea (2.9 %). CONCLUSIONS: Our results show that a de Gramont-based DCF regimen may have tolerable toxicities and be an effective and convenient palliative treatment for advanced gastric cancer.
    Gastric Cancer 10/2012; · 3.99 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: We aimed to investigate the impact of adjuvant systemic therapy with modern chemotherapy combinations on survival outcomes in patients with resected liver-confined metastases from colorectal carcinomas, and whether addition of bevacizumab (BEV) provides further benefit. Methods: A total of 229 consecutive patients who underwent resection for liver-confined colorectal liver metastases were retrospectively analyzed. Results: Of 229 patients, 204 who received chemotherapy with fluoropyrimidine-based (n = 27), irinotecan-based (n = 84) and oxaliplatin-based (n = 93) combinations were analyzed. Among these, 87 patients received BEV while 117 did not (NoBEV). With a median follow-up of 27 months after metastasectomy, the median recurrence-free survival (RFS) and overall survival (OS) were 17 and 53 months, respectively. OS rates at 3 and 5 years were 71% and 40%, respectively. No significant differences were found in the median RFS (p = 0.744) and OS (p = 0.440) among different chemotherapy regimens. The median RFS (p = 0.375) and OS (p = 0.251) were similar in BEV and NoBEV arms. In multivariate analysis, having 4 liver metastases was the only negative independent factor on both RFS and OS, while positive surgical margin was another negative independent factor for RFS. Conclusion: Chemotherapy type and addition of BEV have no impact on both RFS and OS in the adjuvant setting following complete resection of colorectal liver metastases.
    Oncology 10/2012; 84(1):14-21. · 2.17 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: To evaluate the factors that have an impact on the development of brain metastasis in patients with breast cancer. Materials and Methods: Among the patients who were followed-up and treated for breast cancer between January 2000 and January 2010, the ones with brain metastasis were included to the analysis. Metastatic breast cancer patients without brain metastasis, which had similar duration of follow-up and median age were included as the control group. Both group were compared for prognostic and predictive factors in terms of relationship between with or without brain metastasis and survival. Results: There were a total of 63 female patients with metastatic breast cancer who had brain metastasis and the researchers enrolled the same number of female patients as the control group. In the univariate analysis, as a significant finding, it was found that, the patients with breast cancer who had brain metastasis had vascular invasion positivity, human epidermal growth factor receptor-2 (HER-2) positivity, a rare detection of invasive lobular carcinoma component in the tumor, estrogen receptor negativity, and no bone and liver metastasis and they did not receive chemotherapy due to several reasons after the detection of metastasis in any organ. In the multivariate analysis, HER-2 positivity, no bone and liver metastasis and not receiving chemotherapy due to several reasons after the detection of metastasis in any organ were detected as significant findings. Conclusions: As the prognostic and predictive factors showing the development of brain metastasis in breast cancer patients may be identified, follow-up also including the brain is important in order to take preventive measures.
    Journal of cancer research and therapeutics 10/2012; 8(4):542-8. · 0.83 Impact Factor

Publication Stats

296 Citations
102.98 Total Impact Points

Institutions

  • 2001–2014
    • Dokuz Eylul University
      • • Faculty of Medicine
      • • The Institute of Oncology
      • • Department of Internal Medicine
      Ismir, İzmir, Turkey
  • 2013
    • Ataturk University
      • Department of Medical Biology
      Kalikala, Erzurum, Turkey
  • 2012–2013
    • Gazi University
      • • Department of Medical Oncology
      • • Faculty of Medicine
      Engüri, Ankara, Turkey
  • 2009
    • Izmir Bozkaya Research and Training Hospital
      Ismir, İzmir, Turkey
  • 2008
    • Pamukkale University
      • Department of Medical Biology
      Denisli, Denizli, Turkey